{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:33:16Z","timestamp":1789720396508,"version":"4.0.1"},"reference-count":287,"publisher":"American Chemical Society (ACS)","issue":"6","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The eye and eyesight are exquistly designed and are precious, and yet we often take them for granted. Good vision is critical for our long-term survival and for humanity\u2019s enduring progress. Unfortunately, since ocular diseases do not culminate in life-and-death scenarios, awareness of the plight of millions of people suffering from such eye ailments is not publicized as other diseases. However, losing eyesight or falling victim to visual impairment is a frightening outlook for most people. Glaucoma, a collection of chronic optic neuropathies, of which the most prevalent form, primary open-angle glaucoma (POAG), is the second leading cause of irreversible blindness. POAG currently afflicts &amp;gt;70 million people worldwide and is an insidious, progressive, silent thief of sight that is asymptomatic. On the other hand, allergic conjunctivitis (AC), and the associated rhinitis (\u201chay-fever\u201d), frequently victimizes a huge number of people worldwide, especially during seasonal changes. While not life-threatening, sufferers of AC soon learn the value of drugs to treat their signs and symptoms of AC as they desire rapid relief to overcome the ocular itching\/pain, redness, and tearing AC causes. Herein, I will describe the collective efforts of many researchers whose industrious, diligent, and dedicated team work resulted in the discovery, biochemical\/pharmacological characterization, development and eventual launch of drugs to treat AC (e.g., olopatadine [Patanol\/Pataday\/Pazeo] and emedastine [Emedine]), and for treating ocular hypertension and POAG (e.g., travoprost [Travatan ] and Simbrinza). This represents a personal perspective.<\/jats:p>","DOI":"10.1021\/acsptsci.0c00137","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T01:45:08Z","timestamp":1604540708000},"page":"1391-1421","source":"Crossref","is-referenced-by-count":11,"title":["Discovery to Launch of Anti-allergy (Emadine; Patanol\/Pataday\/Pazeo)\nand Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation\nof Novel Pharmacological Tools Such as AL-8810"],"prefix":"10.1021","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4432-730X","authenticated-orcid":true,"given":"Najam A.","family":"Sharif","sequence":"first","affiliation":[{"name":"University of North Texas Health Science Center , , ,","place":["Fort Worth, Texas, United States, 76107"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2026081416171410100_cit1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2222.1988.tb02837.x","article-title":"Ocular allergy","volume":"18","author":"Allansmith","year":"1988","journal-title":"Clin. Exp. Allergy"},{"key":"2026081416171410100_cit2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0039-6257(93)90036-7","article-title":"Conjunctivitis of allergic\norigin: immunologic mechanisms\nand current approaches to therapy","volume":"38","author":"Abelson","year":"1993","journal-title":"Surv. Ophthalmol."},{"key":"2026081416171410100_cit3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00347-017-0580-1","article-title":"Seasonal allergic conjunctivitis","volume":"114","author":"Schro\u0308der","year":"2017","journal-title":"Ophthalmologe"},{"key":"2026081416171410100_cit4","first-page":"225","article-title":"The diagnosis and treatment of glaucoma","volume":"117","author":"Schuster","year":"2020","journal-title":"Dtsch\nArztebl Int."},{"key":"2026081416171410100_cit5","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas","year":"2017","journal-title":"Lancet"},{"key":"2026081416171410100_cit6","first-page":"22","article-title":"Ocular\nhypertension and glaucoma: a review and current perspectives","volume":"2","author":"Sharif","year":"2017","journal-title":"Int. J. Ophthalmol. Vis. Sci."},{"key":"2026081416171410100_cit7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/jop.2017.0125","article-title":"iDrugs\nand iDevices discovery and development - preclinical assays, techniques\nand animal model studies for ocular hypotensives and neuroprotectants","volume":"34","author":"Sharif","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/978-3-319-56637-5_54-1","article-title":"Pharmacodynamic Evaluation: Ocular Pharmacology","volume-title":"Drug Discovery and Evaluation: Methods in Clinical Pharmacology","author":"Sharif","year":"2020"},{"key":"2026081416171410100_cit9","author":"WHO","year":"2018"},{"key":"2026081416171410100_cit10","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections\nof glaucoma burden through 2040","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"2026081416171410100_cit11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2500\/aap.2017.38.4003","article-title":"Diagnosis\nand management of allergic\nconjunctivitis in pediatric patients","volume":"38","author":"Berger","year":"2017","journal-title":"Allergy\nAsthma Proc."},{"key":"2026081416171410100_cit12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.anai.2019.11.014","article-title":"Diagnosis and management\nof allergic conjunctivitis","volume":"124","author":"Bielory","year":"2020","journal-title":"Ann. Allergy, Asthma,\nImmunol."},{"key":"2026081416171410100_cit13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/bph.14327","article-title":"Discovery, characterization and clinical utility of\nprostaglandin agonists for treatment of glaucoma","volume":"176","author":"Klimko","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit14","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.4103\/1673-5374.235017","article-title":"Glaucomatous\noptic neuropathy treatment options: the promise of novel therapeutics,\ntechniques and tools to help preserve vision","volume":"13","author":"Sharif","year":"2018","journal-title":"Neural Regener. Res."},{"issue":"1 Suppl. 1","key":"2026081416171410100_cit15","first-page":"49","article-title":"Allergic conjunctivitis:\ncurrent concepts on pathogenesis and management","volume":"32","author":"Sacchetti","year":"2018","journal-title":"J. Biol. Regul Homeost Agents"},{"key":"2026081416171410100_cit16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/187221311794474883","article-title":"Recent\npatents and\nemerging therapeutics in the treatment of allergic conjunctivitis","volume":"5","author":"Mishra","year":"2011","journal-title":"Recent Pat. Inflammation Allergy Drug Discovery"},{"key":"2026081416171410100_cit17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/164_2016_73","article-title":"Ocular pharmacology\nof tear film, dry eye, and allergic conjunctivitis","volume":"242","author":"Gulati","year":"2016","journal-title":"Handb. Exp. Pharmacol."},{"key":"2026081416171410100_cit18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1126\/science.1233765","article-title":"The cells and circuitary for itch responses in mice","volume":"340","author":"Mishra","year":"2013","journal-title":"Science"},{"key":"2026081416171410100_cit19","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.2500\/ar.2016.7.0158","article-title":"Treating allergic conjunctivitis:\nA once-daily medication that provides 24-h symptom relief","volume":"7","author":"Carr","year":"2016","journal-title":"Allergy Rhinol."},{"key":"2026081416171410100_cit20","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jama.2013.280318","article-title":"Conjunctivitis: a systematic review of diagnosis and\ntreatment","volume":"310","author":"Azari","year":"2013","journal-title":"J. Amer Med. Assoc."},{"key":"2026081416171410100_cit21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3109\/02713683.2012.747617","article-title":"New twists to an old\nstory: novel concepts in the pathogenesis of allergic eye disease","volume":"38","author":"Saban","year":"2013","journal-title":"Curr. Eye Res."},{"key":"2026081416171410100_cit22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/0091-6749(90)90075-F","article-title":"Inflammatory\nmediator\nrelease on conjunctival provocation of allergic subjects with allergen","volume":"85","author":"Proud","year":"1990","journal-title":"J. Allergy Clin. Immunol."},{"issue":"569","key":"2026081416171410100_cit23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00569","article-title":"Mast cell\nmediators: their differential\nrelease and the secretory pathways involved","volume":"5","author":"Moon","year":"2014","journal-title":"Front. Immunol."},{"key":"2026081416171410100_cit24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2500\/108854101778148782","article-title":"Conjunctival\nmast\ncells in ocular allergic disease","volume":"22","author":"Graziano","year":"2001","journal-title":"Allergy Asthma\nProc."},{"key":"2026081416171410100_cit25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/00130832-200210000-00009","article-title":"Human ocular mast cells","volume":"2","author":"Church","year":"2002","journal-title":"Curr.\nOpin Allergy Clin Immunol."},{"issue":"448","key":"2026081416171410100_cit26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/ddr.430330408","article-title":"Histamine\nreceptor subtype affinities, selectivities\nand potencies of emedastine, a novel H1 selective antagonist,\nand other ocularly employed antihistamines","volume":"33","author":"Sharif","year":"1994","journal-title":"Drug Dev. Res."},{"key":"2026081416171410100_cit27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/jop.1994.10.653","article-title":"Emedastine: a potent, high affinity histamine H1 selective antagonist for ocular use. receptor binding and\nsecond messenger studies","volume":"10","author":"Sharif","year":"1994","journal-title":"J. Ocul. Pharmacol.\nTher."},{"key":"2026081416171410100_cit28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/exer.1996.0105","article-title":"Human conjunctival epithelial cells\nexpress histamine-1 receptors coupled to phosphoinositide turnover\nand intracellular calcium mobilization: role in ocular allergic &\ninflammatory diseases","volume":"3","author":"Sharif","year":"1996","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1089\/jop.1996.12.401","article-title":"Olopatadine\n(AL 4943A): Ligand binding and functional\nstudies on a novel, long acting H1 selective histamine\nantagonist for use in allergic conjunctivitis","volume":"12","author":"Sharif","year":"1996","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit30","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0022-3565(25)20776-5","article-title":"Characterization of\nthe ocular anti allergic and anti histaminic effects of olopatadine\n(AL 4943A), a novel drug for treating ocular allergic diseases","volume":"278","author":"Sharif","year":"1996","journal-title":"J. Pharmacol. Expt Ther."},{"key":"2026081416171410100_cit31","first-page":"255","article-title":"Anti histamines, topical ocular","volume-title":"Burger\u2019s\nMedicinal Chemistry & Drug Discovery","author":"Sharif","year":"1997","edition":"5"},{"key":"2026081416171410100_cit32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/jop.1997.13.321","article-title":"Pharmacological analysis\nof mast cell mediator and neurotransmitter receptors coupled to adenylate\ncyclase and phospholipase C on immunocytochemically-defined human\nconjunctival epithelial cells","volume":"13","author":"Sharif","year":"1997","journal-title":"J. Ocul. Pharmacol.\nTher."},{"key":"2026081416171410100_cit33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bjp.0701168","article-title":"The expression of functionally-coupled\nbradykinin receptors in human corneal epithelial cells and their pharmacological\ncharacterization with agonists and antagonists","volume":"121","author":"Wiernas","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/sj.bjp.0701700","article-title":"Effects of bradykinin\non signal transduction, cell proliferation, and cytokine, prostaglandin\nE2 and collagenase-1 release from human corneal epithelial\ncells","volume":"123","author":"Wiernas","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit35","first-page":"2562","article-title":"Human corneal epithelial\ncell functional responses to inflammatory agents and their antagonists","volume":"39","author":"Sharif","year":"1998","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2026081416171410100_cit36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/sj.bjp.0702194","article-title":"Pharmacology of\n[3H]-pyrilamine binding and the histamine-induced phosphoinositide\nturnover, Ca2+-mobilization and cytokine release from human\ncorneal epithelial cells","volume":"125","author":"Sharif","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit37","first-page":"1091","article-title":"Immortalized human corneal\nepithelial cells for ocular toxicity and inflammation studies","volume":"40","author":"Offord","year":"1999","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2026081416171410100_cit38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/jop.2009.0102","article-title":"Platelet-activating factor-induced intracellular signaling\nand release of cytokines and prostaglandin E2 in immortalized human\ncorneal epithelial cells","volume":"26","author":"Sharif","year":"2010","journal-title":"J. Ocul. Pharmacol.\nTher."},{"key":"2026081416171410100_cit39","first-page":"336","article-title":"Isolation of human conjunctival\nmast cells and epithelial cells: tumor necrosis factor-alpha from\nmast cells affects intercellular adhesion molecule-1 expression on\nepithelial cells","volume":"39","author":"Cook","year":"1998","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2026081416171410100_cit40","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1167\/iovs.02-0721","article-title":"Differential and\ncooperative effects of TNFalpha, IL-1beta, and IFNgamma on human conjunctival\nepithelial cell receptor expression and chemokine release","volume":"44","author":"Stahl","year":"2003","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1006\/exer.1998.0528","article-title":"The role of conjunctival\nepithelial cells in chronic ocular allergic disease","volume":"67","author":"Hingorani","year":"1998","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s11882-003-0098-2","article-title":"Epithelial cells in ocular allergy","volume":"3","author":"Irkec\u0327","year":"2003","journal-title":"Curr. Allergy Asthma Rep."},{"key":"2026081416171410100_cit43","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1167\/iovs.05-1084","article-title":"Clusters of corneal\nepithelial cells reside ectopically in human conjunctival epithelium","volume":"47","author":"Kawasaki","year":"2006","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/jid.1960.78","article-title":"Proteolytic\nactivity in development of pain and itching.\nCutaneous reactions to bradykinin and kallikrein","volume":"35","author":"Cormia","year":"1960","journal-title":"J. Invest. Dermatol."},{"key":"2026081416171410100_cit45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2340\/00015555573743","article-title":"Pruritogenic activity of prostaglandin E2","volume":"57","author":"Ha\u0308germark","year":"1977","journal-title":"Acta Derm Venereol."},{"key":"2026081416171410100_cit46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000211009","article-title":"Peripheral\nand central mediators of itch","volume":"5","author":"Ha\u0308germark","year":"2004","journal-title":"Skin Pharmacol."},{"key":"2026081416171410100_cit47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2500\/108854194778816472","article-title":"Human mast cell\nheterogeneity","volume":"15","author":"Irani","year":"1994","journal-title":"Allergy Asthma Proc."},{"key":"2026081416171410100_cit48","first-page":"261","article-title":"Platelet-activating factor (PAF)\nand PAF antagonists in asthma","volume":"7","author":"Hosford","year":"1990","journal-title":"Crit.  Rev. Ther.\nDrug Carrier Syst."},{"key":"2026081416171410100_cit49","first-page":"313","article-title":"SCH-37370: a new drug\ncombining antagonism of platelet-activating factor (PAF) with antagonism\nof histamine","volume":"34","author":"Billah","year":"1991","journal-title":"Agents Actions Suppl."},{"key":"2026081416171410100_cit50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jop.1991.7.313","article-title":"Allergic conjunctivitis:\na survey of new antihistamines","volume":"7","author":"Berdy","year":"1991","journal-title":"J. Ocul. Pharmacol.\nTher."},{"key":"2026081416171410100_cit51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/09273949609069126","article-title":"Human conjunctival mast\ncell responses in vitro to various secretagogues","volume":"4","author":"Miller","year":"1996","journal-title":"Ocul. Immunol. Inflammation"},{"key":"2026081416171410100_cit52","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S1081-1206(10)62513-6","article-title":"Olopatadine\ninhibits\nTNFalpha release from human conjunctival mast cells","volume":"84","author":"Cook","year":"2000","journal-title":"Ann. Allergy, Asthma, Immunol."},{"key":"2026081416171410100_cit53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1081-1206(10)62926-2","article-title":"Olopatadine inhibits\nanti-immunoglobulin E-stimulated conjunctival mast cell upregulation\nof ICAM-1 expression on conjunctival epithelial cells","volume":"87","author":"Cook","year":"2001","journal-title":"Ann. Allergy, Asthma, Immunol."},{"key":"2026081416171410100_cit54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/1568010023344733","article-title":"Mechanisms of antihistamines\nand mast cell stabilizers in ocular allergic inflammation","volume":"1","author":"Cook","year":"2002","journal-title":"Curr. Drug Targets: Inflammation Allergy"},{"key":"2026081416171410100_cit55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1081-1206(10)61712-7","article-title":"The promotion of eosinophil\ndegranulation and adhesion to conjunctival epithelial cells by IgE-activated\nconjunctival mast cells","volume":"92","author":"Cook","year":"2004","journal-title":"Ann. Allergy, Asthma,\nImmunol."},{"key":"2026081416171410100_cit56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/jop.1996.12.389","article-title":"The in vitro and in\nvivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic\/antihistaminic\nagent","volume":"12","author":"Yanni","year":"1996","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit57","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1081-1206(10)63063-3","article-title":"Comparative effects\nof topical ocular anti-allergy drugs on human conjunctival mast cells","volume":"79","author":"Yanni","year":"1997","journal-title":"Ann. Allergy, Asthma, Immunol."},{"key":"2026081416171410100_cit58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1600-0420.1999.tb01171.x","article-title":"A current appreciation\nof sites for pharmacological intervention in allergic conjunctivitis:\neffects of new topical ocular drugs","volume":"77","author":"Yanni","year":"1999","journal-title":"Acta Ophthalmol.\nScand."},{"key":"2026081416171410100_cit59","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/archopht.117.5.643","article-title":"Inhibition of histamine-induced\nhuman conjunctival epithelial cell responses by ocular allergy drugs","volume":"117","author":"Yanni","year":"1999","journal-title":"Arch. Ophthalmol."},{"key":"2026081416171410100_cit60","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000069459","article-title":"Histamine-stimulated\ncytokine secretion\nfrom human conjunctival epithelial cells: inhibition by the histamine\nH1 antagonist emedastine","volume":"115","author":"Weimer","year":"1998","journal-title":"Int. Arch.\nAllergy Immunol."},{"key":"2026081416171410100_cit61","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1046\/j.1365-2222.1997.1600959.x","article-title":"Immunolocalization of\ncytokines to mast cells in normal and allergic conjunctiva","volume":"27","author":"Macleod","year":"1997","journal-title":"Clin. Exp. Allergy"},{"key":"2026081416171410100_cit62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1089\/jop.1994.10.665","article-title":"Preclinical efficacy\nof emedastine, a potent, selective histamine H1 antagonist for topical\nocular use","volume":"10","author":"Yanni","year":"1994","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit63","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0002-9394(00)00947-8","article-title":"Clinical evaluation\nof twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus\nlevocabastine 0.05% eye drops in patients with allergic conjunctivitis","volume":"131","author":"Verin","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"2026081416171410100_cit64","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-0420.1999.tb01173.x","article-title":"Comparison of the topical\nocular\nantiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac\n0.5% ophthalmic solution in a clinical model of allergic conjunctivitis","volume":"228","author":"Discepola","year":"1999","journal-title":"Acta Ophthalmol. Scand."},{"key":"2026081416171410100_cit65","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0002-9394(00)00689-9","article-title":"Emedastine\nophthalmic solution 0.05%\nversus levocabastine ophthalmic suspension 0.05% in the treatment\nof allergic conjunctivitis using the conjunctival allergen challenge\nmodel","volume":"130","author":"Netland","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"2026081416171410100_cit66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00044011-200323050-00003","article-title":"Onset and duration of\naction of ketotifen 0.025% and emedastine 0.05% in seasonal allergic\nconjunctivitis: efficacy after repeated pollen challenges in the Vienna\nchallenge chamber","volume":"23","author":"Horak","year":"2003","journal-title":"Clin. Drug Invest."},{"key":"2026081416171410100_cit67","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1248\/cpb.40.2552","article-title":"Synthesis\nof a dibenz\u00ad[b,e]\u00adoxepin- bovine serum albumin conjugate for radioimmunoassay\nof KW-4679 ((Z)-11-[3-(dimethylamino)\u00adpropylidene]-6,11-dihydrodibenz\u00ad[b,e]\u00adoxepin-2-acetic\nacid hydrochloride)","volume":"40","author":"Ohshima","year":"1992","journal-title":"Chem. Pharm. Bull."},{"key":"2026081416171410100_cit68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0014-2999(97)01620-8","article-title":"Unique binding pocket\nfor KW-4679 in the histamine H1 receptor","volume":"345","author":"Nonaka","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"2026081416171410100_cit69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/09273949709085060","article-title":"Secretion\nof proinflammatory\ncytokines by human conjunctival epithelial cells","volume":"5","author":"Gamache","year":"1997","journal-title":"Ocul. Immunol. Inflammation"},{"key":"2026081416171410100_cit70","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1076\/ocii.11.4.247.18261","article-title":"Interactions\nof olopatadine\nand selected antihistamines with model and natural membranes","volume":"11","author":"Brockman","year":"2003","journal-title":"Ocul. Immunol. Inflammation"},{"key":"2026081416171410100_cit71","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1081-1206(10)62814-1","article-title":"Evaluation\nof olopatadine, a new ophthalmic antiallergic agent with dual activity,\nusing the conjunctival allergen challenge model","volume":"81","author":"Abelson","year":"1998","journal-title":"Ann. Allergy, Asthma, Immunol."},{"key":"2026081416171410100_cit72","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0002-9394(98)00044-0","article-title":"Combined analysis of two studies\nusing the conjunctival\nallergen challenge model to evaluate olopatadine hydrochloride, a\nnew ophthalmic antiallergic agent with dual activity","volume":"125","author":"Abelson","year":"1998","journal-title":"Am. J. Ophthalmol."},{"key":"2026081416171410100_cit73","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1600-0420.1999.tb01175.x","article-title":"The added benefit of local Patanol\ntherapy when combined\nwith systemic Claritin for the inhibition of ocular itching in the\nconjunctival antigen challenge model","volume":"77","author":"Abelson","year":"1999","journal-title":"Acta Ophthalmol.\nScand."},{"key":"2026081416171410100_cit74","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1034\/j.1600-0420.2000.078s230060.x","article-title":"An evaluation of onset and duration of action of patanol\n(olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin\n(loratadine 10 mg) tablets in acute allergic conjunctivitis in the\nconjunctival allergen challenge model","volume":"78","author":"Abelson","year":"2000","journal-title":"Acta\nOphthalmol. Scand."},{"key":"2026081416171410100_cit75","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0149-2918(01)80106-5","article-title":"Evaluation\nof the efficacy of olopatadine\nhydrochloride 0.1% ophthalmic solution and azelastine hydrochloride\n0.05% ophthalmic solution in the conjunctival allergen challenge model","volume":"23","author":"Spangler","year":"2001","journal-title":"Clin. Ther."},{"key":"2026081416171410100_cit76","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/S0149-2918(00)83044-1","article-title":"Comparison of the clinical\nefficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic\nsolution and nedocromil sodium 2% ophthalmic solution in the human\nconjunctival allergen challenge model","volume":"22","author":"Butrus","year":"2000","journal-title":"Clin.\nTher."},{"key":"2026081416171410100_cit77","first-page":"69","article-title":"Preclinical and clinical\nantiallergic effect of olopatadine 0.2% solution 24 h after topical\nocular administration","volume":"25","author":"Vogelson","year":"2004","journal-title":"Allergy Asthma Proc."},{"key":"2026081416171410100_cit78","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1517\/17425255.4.4.453","article-title":"Olopatadine 0.2%\nophthalmic solution: the first ophthalmic\nantiallergy agent with once-daily dosing","volume":"4","author":"Abelson","year":"2008","journal-title":"Expert\nOpin. Drug Metab. Toxicol."},{"key":"2026081416171410100_cit79","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S0149-2918(04)80065-1","article-title":"Clinical\nefficacy of\nolopatadine hydrochloride ophthalmic solution 0.2% compared with placebo\nin patients with allergic conjunctivitis or rhinoconjunctivitis: a\nrandomized, double-masked environmental study","volume":"26","author":"Abelson","year":"2004","journal-title":"Clin. Ther."},{"key":"2026081416171410100_cit80","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1517\/14656566.2015.1040760","article-title":"Advances in pharmacotherapy\nfor allergic conjunctivitis","volume":"16","author":"Abelson","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"2026081416171410100_cit81","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/j.1365-2222.2007.02782.x","article-title":"Ocular anti-allergic\ncompounds selectively inhibit human mast cell cytokines in vitro and\nconjunctival cell infiltration in vivo","volume":"37","author":"Galatowicz","year":"2007","journal-title":"Clin.\nExp. Allergy"},{"key":"2026081416171410100_cit82","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ICO.0000000000000562","article-title":"Phase 3 Randomized double-masked\nstudy of efficacy and safety of once-daily 0.77% olopatadine hydrochloride\nophthalmic solution in subjects with allergic conjunctivitis using\nthe conjunctival allergen challenge model","volume":"34","author":"McLaurin","year":"2015","journal-title":"Cornea"},{"key":"2026081416171410100_cit83","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/OPTH.S131830","article-title":"Pooled analysis\nof two studies evaluating efficacy\nand safety of olopatadine hydrochloride 0.77% in patients with allergic\nconjunctivitis","volume":"11","author":"McLaurin","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"2026081416171410100_cit84","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/S0149-2918(08)80050-1","article-title":"Ocular comfort\nand drying effects\nof three topical antihistamine\/mast cell stabilizers in adults with\nallergic conjunctivitis: a randomized, double-masked crossover study","volume":"30","author":"Torkildsen","year":"2008","journal-title":"Clin. Ther."},{"key":"2026081416171410100_cit85","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/ACI.0b013e328357d3ba","article-title":"Ophthalmic antihistamines\nand H1-H4\nreceptors","volume":"12","author":"Wade","year":"2012","journal-title":"Curr. Opin Allergy Clin Immunol."},{"key":"2026081416171410100_cit86","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/jovr.jovr_85_17","article-title":"Topical\nolopatadine hydrochloride\nversus ketotifen fumarate for allergic conjunctivitis","volume":"13","author":"Patel","year":"2018","journal-title":"J. Ophthalmic Vis Res."},{"key":"2026081416171410100_cit87","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/JRLCR.S39369","article-title":"Alcaftadine, a new antihistamine with combined antagonist\nactivity at histamine H1, H2, and H4 receptors","volume":"5","author":"Gallois-Bernos","year":"2012","journal-title":"J. Recept., Ligand Channel Res."},{"key":"2026081416171410100_cit88","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuroscience.2011.06.002","article-title":"Histamine H1, H3 and\nH4 receptors are involved in pruritus","volume":"190","author":"Rossbach","year":"2011","journal-title":"Neuroscience"},{"key":"2026081416171410100_cit89","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/jop.2010.0153","article-title":"Clinical pharmacology\nof alcaftadine, a novel antihistamine for the prevention of allergic\nconjunctivitis","volume":"27","author":"Bohets","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit90","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00011-009-8245-4","article-title":"The histamine\nH4 receptor\nantagonist JNJ7777120 induces increases in the histamine content of\nthe rat conjunctiva","volume":"58","author":"Zampeli","year":"2009","journal-title":"Inflammation Res."},{"key":"2026081416171410100_cit91","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bcp.2012.04.004","article-title":"Incomplete activation\nof human eosinophils via the histamine H4-receptor: evidence\nfor ligand-specific receptor conformations","volume":"84","author":"Reher","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"2026081416171410100_cit92","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/2040622315612745","article-title":"Ocular itch associated\nwith allergic\nconjunctivitis: latest evidence and clinical management","volume":"7","author":"Ackerman","year":"2016","journal-title":"Ther. Adv. Chronic Dis."},{"key":"2026081416171410100_cit93","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/ACI.0b013e328364d86a","article-title":"Immunomodulators for conjunctivitis","volume":"13","author":"Pacharn","year":"2013","journal-title":"Curr. Opin Allergy Clin Immunol."},{"key":"2026081416171410100_cit94","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/all.13334","article-title":"Clinical implications\nof mast cell\ninvolvement in allergic conjunctivitis","volume":"73","author":"Komi","year":"2018","journal-title":"Allergy"},{"key":"2026081416171410100_cit95","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1111\/bph.14458","article-title":"DS-70, a novel and potent\n\u03b1 (4) integrin antagonist, is an effective treatment for experimental\nallergic conjunctivitis in guinea pigs","volume":"175","author":"Dattoli","year":"2018","journal-title":"Br.\nJ. Pharmacol."},{"key":"2026081416171410100_cit96","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5114\/aoms.2017.68534","article-title":"New antihistamines \u2013 perspectives in the treatment\nof some allergic and inflammatory disorders","volume":"2","author":"Tatarkiewicz","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"2026081416171410100_cit97","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.ophtha.2014.06.035","article-title":"Optic nerve head deformation in glaucoma:\nthe temporal relationship between optic nerve head surface depression\nand retinal nerve fiber layer thinning","volume":"121","author":"Xu","year":"2014","journal-title":"Ophthalmology"},{"key":"2026081416171410100_cit98","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ophtha.2008.01.013","article-title":"Cerebrospinal fluid pressure is decreased\nin primary open-angle glaucoma","volume":"115","author":"Berdahl","year":"2008","journal-title":"Ophthalmology"},{"key":"2026081416171410100_cit99","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/2008-322X.183914","article-title":"Update on normal tension\nglaucoma","volume":"11","author":"Mallick","year":"2016","journal-title":"J. Ophthalmic Vis Res."},{"key":"2026081416171410100_cit100","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ophtha.2012.08.047","article-title":"Reversal of\nlamina cribrosa displacement after intraocular pressure reduction\nin open-angle glaucoma","volume":"120","author":"Lee","year":"2013","journal-title":"Ophthalmology"},{"key":"2026081416171410100_cit101","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.preteyeres.2004.06.001","article-title":"The optic nerve head\nas a biomechanical structure; a new paradigm for understanding the\nrole of IOP-related stress and strain in the pathophysiology of glaucomatous\noptic nerve head damage","volume":"24","author":"Burgoyne","year":"2005","journal-title":"Prog. Retinal Eye Res."},{"key":"2026081416171410100_cit102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.16966\/2639-152X.110","article-title":"Correlation of lamina\ncribosa and\nstandard automated perimeter findings in glaucoma and non-glaucoma\npatients","volume":"2","author":"Daguman","year":"2019","journal-title":"J. Ophthal. Studies"},{"key":"2026081416171410100_cit103","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.exer.2010.08.004","article-title":"Glaucomatous\ncupping\nof the lamina cribrosa: a review of the evidence for active progressive\nremodeling as a mechanism","volume":"93","author":"Downs","year":"2011","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit104","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000267739","article-title":"Evidence of\nconstriction of optic axons at the lamina cribrosa in the normotensive\neye in humans and other mammals","volume":"27","author":"Hollander","year":"1995","journal-title":"Ophthalmic\nRes."},{"key":"2026081416171410100_cit105","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1350-9462(97)00006-2","article-title":"Optic nerve blood-flow\nabnormalities\nin glaucoma","volume":"17","author":"Flammer","year":"1998","journal-title":"Prog. Retinal Eye Res."},{"key":"2026081416171410100_cit106","doi-asserted-by":"publisher","first-page":"7286","DOI":"10.1167\/iovs.15-17879","article-title":"Compromized optic nerve blood flow and autoregulation\nsecondary to\nneural degeneration","volume":"56","author":"Cull","year":"2015","journal-title":"Invest. Ophthalmol. Visual\nSci."},{"key":"2026081416171410100_cit107","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/0002-9394(89)90491-1","article-title":"Age-related changes\nin the extracellular matrix of\nthe human optic nerve head","volume":"107","author":"Hernandez","year":"1989","journal-title":"Am. J. Ophthalmol."},{"key":"2026081416171410100_cit108","first-page":"1182","article-title":"Oxidative\nstress, mitochondrial dysfunction and calcium overload in human lamina\ncribrosa cells from glaucoma donors","volume":"17","author":"McElnea","year":"2011","journal-title":"Mol. Vis."},{"key":"2026081416171410100_cit109","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.exer.2010.03.008","article-title":"Mitochondria: Their role in ganglion\ncell death and\nsurvival in primary open angle glaucoma","volume":"90","author":"Osborne","year":"2010","journal-title":"Exp.\nEye Res."},{"key":"2026081416171410100_cit110","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejphar.2016.04.032","article-title":"Glaucoma:\nfocus on mitochondria in relation to pathogenesis and neuroprotection","volume":"787","author":"Osborne","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"2026081416171410100_cit111","first-page":"764","article-title":"Obstructed\naxonal transport of BDNF and its receptor TrkB in experimental glaucoma","volume":"41","author":"Pease","year":"2000","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2026081416171410100_cit112","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1167\/iovs.12-9483i","article-title":"The cell and molecular biology of\nglaucoma: axonopathy and the brain","volume":"53","author":"Calkins","year":"2012","journal-title":"Invest.\nOphthalmol. Visual Sci."},{"key":"2026081416171410100_cit113","first-page":"87","article-title":"Retinal\nATP and phosphorus metabolites: reduction by hypoxia and recovery\nwith MK-801 and diltiazem","volume":"28","author":"Thomas","year":"2000","journal-title":"Med. Sci. Res."},{"key":"2026081416171410100_cit114","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/biology8020031","article-title":"Mitochondrial dysfunction in the\naging retina","volume":"8","author":"Eells","year":"2019","journal-title":"Biology"},{"key":"2026081416171410100_cit115","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1167\/iovs.61.8.23","article-title":"Unaltered perception\nof suprathreshold contrast in early glaucoma despite sensitivity loss","volume":"61","author":"Bham","year":"2020","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit116","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00003495-200059030-00003","article-title":"Pharmacological therapy for glaucoma:\na review","volume":"59","author":"Hoyng","year":"2000","journal-title":"Drugs"},{"key":"2026081416171410100_cit117","first-page":"349","article-title":"The ocular\nhypotensive effects and side effects of prostaglandins on the eyes\nof experimental animals","volume":"312","author":"Bito","year":"1989","journal-title":"Prog. Clin Biol. Res."},{"key":"2026081416171410100_cit118","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0014-4835(90)90143-I","article-title":"Eicosanoids\nas a new class of ocular hypotensive agents. 3. Prostaglandin A2\u20131-isopropyl\nester is the most potent reported hypotensive agent on feline eyes","volume":"50","author":"Bito","year":"1990","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit119","first-page":"1126","article-title":"A new approach to the medical management of glaucoma,\nfrom the bench to the clinic, and beyond: The Proctor Lecture","volume":"42","author":"Bito","year":"2001","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2026081416171410100_cit120","first-page":"1","article-title":"The ocular effects of eicosanoids\nand other autacoids: historic background and the need for a broader\nperspective","volume":"312","author":"Stjernschantz","year":"1989","journal-title":"Prog. Clin Biol. Res."},{"key":"2026081416171410100_cit121","first-page":"1134","article-title":"From PGF\u00ad(2alpha)-isopropyl ester\nto latanoprost: a\nreview of the development of xalatan: the Proctor Lecture","volume":"42","author":"Stjernschantz","year":"2001","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2026081416171410100_cit122","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.exer.2003.11.016","article-title":"Studies on ocular inflammation and development of a\nprostaglandin analogue for glaucoma treatment","volume":"78","author":"Stjernschantz","year":"2004","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit123","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1167\/iovs.07-0035","article-title":"Effect\nof 15-keto latanoprost on intraocular pressure and aqueous humor dynamics\nin monkey eyes","volume":"48","author":"Wang","year":"2007","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit124","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1021\/jm00054a008","article-title":"Phenyl-substituted\nprostaglandins: potent and selective antiglaucoma agents","volume":"36","author":"Resul","year":"1993","journal-title":"J. Med. Chem."},{"issue":"Suppl 2","key":"2026081416171410100_cit125","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/S0039-6257(97)80007-0","article-title":"Structure-activity relationships and receptor profiles of some ocular\nhypotensive prostanoids","volume":"41","author":"Resul","year":"1997","journal-title":"Surv. Ophthalmol."},{"key":"2026081416171410100_cit126","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1021\/jm990587w","article-title":"Synthesis\nand biological activity of a novel 11\u03b1-homo-(cyclohexyl)-prostaglandin","volume":"43","author":"Klimko","year":"2000","journal-title":"J. Med. Chem."},{"key":"2026081416171410100_cit127","article-title":"Correlation\nof results from preclinical experimental models used for evaluation\nof FP prostaglandin agonists for therapy of glaucoma","volume":"39","author":"Sallee","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2026081416171410100_cit128","article-title":"RT-PCR\nanalysis of prostanoid FP receptor mRNA in human pigmented ocular\ntissues: methodological considerations and results","volume":"S511","author":"Senchyna","year":"2000","journal-title":"Assoc. Res. Vision Opthalmol."},{"issue":"# 4;\nSuppl","key":"2026081416171410100_cit129","article-title":"Autoradiographic visualization and\ncharacterization of FP-prostaglandin receptors in human eyes using\n[3H]-PGF2\u03b1 and [3H]\u00adAL-5848,\nthe acid form of travoprost","volume":"40","author":"Sharif","year":"1999","journal-title":"Invest. Ophthalmol.\nVis. Sci."},{"key":"2026081416171410100_cit130","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/jop.1999.15.271","article-title":"Pharmacological characterization\nof [3H]-ifenprodil binding to polyamine binding sites on\nrabbit and rat retinal homogenates: role in neuroprotection?","volume":"15","author":"Sharif","year":"1999","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit131","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/bjo.83.2.236","article-title":"Human retina contains\npolyamine-sensitive\n[3H]-ifenprodil binding sites: implications for neuroprotection?","volume":"83","author":"Sharif","year":"1999","journal-title":"Br. J. Ophthalmol."},{"issue":"2000","key":"2026081416171410100_cit132","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/sj.bjp.0703525","article-title":"Pharmacological characterization\nof [3H]-prostaglandin E2 binding to the cloned human EP4 prostanoid receptor","volume":"130","author":"Davis","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit133","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1211\/0022357021778655","article-title":"Cloned human EP1 prostanoid\nreceptor pharmacology characterized using radioligand binding techniques","volume":"54","author":"Sharif","year":"2002","journal-title":"J. Pharm. Pharmacol."},{"key":"2026081416171410100_cit134","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1211\/0022357022557","article-title":"Pharmacological characterization\nand identification of EP3 prostanoid receptor binding sites\nin hamster uterus homogenates","volume":"56","author":"Sharif","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"2026081416171410100_cit135","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0022-3565(24)37692-X","article-title":"Pharmacological\nanalysis of [3H]\u00adPGE1\/[3H]\u00adPGE2 and [3H]\u00adPGF2\u03b1 binding in bovine\ncorpus luteum: identification of EP3 and FP prostaglandin\nreceptors and correlation with functional data","volume":"286","author":"Sharif","year":"1998","journal-title":"J. Pharmacol Exp Ther."},{"key":"2026081416171410100_cit136","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1211\/0022357991772989","article-title":"[3H]\u00adAL-5848\n(9-\u03b2-[+]\u00adfluprostenol): carboxylic acid of travoprost (AL-6221),\na novel FP-prostaglandin to study the pharmacology and autoradiographic\nlocalization of the FP receptor","volume":"51","author":"Sharif","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"2026081416171410100_cit137","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(24)39238-9","article-title":"Affinities,\nselectivities, potencies and intrinsic activities of natural and synthetic\nprostanoids using endogenous receptors: focus on DP class prostanoids","volume":"293","author":"Sharif","year":"2000","journal-title":"J. Pharmacol Exp Ther."},{"key":"2026081416171410100_cit138","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/sj.bjp.0703686","article-title":"Pharmacology and\nautoradiography of human DP prostanoid receptors using [3H]-BWA868C, a DP receptor-selective antagonist radioligand","volume":"131","author":"Sharif","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit139","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1211\/0022357001777586","article-title":"AL-3138 antagonizes\nFP prostanoid receptor-mediated inositol phosphates generation: comparison\nwith some purported FP antagonists","volume":"52","author":"Sharif","year":"2000","journal-title":"J. Pharm.\nPharmacol."},{"key":"2026081416171410100_cit140","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/108076802317373905","article-title":"Pharmacological\nand molecular biological (RT-PCR) characterization of functional TP\nprostanoid receptors in immortalized human non-pigmented ciliary epithelial\ncells","volume":"18","author":"Sharif","year":"2002","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit141","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0952-3278(02)00232-6","article-title":"Bimatoprost\n(Lumigan)\nis an agonist at the cloned human ocular FP receptor: real-time FLIPR-based\nintracellular Ca2+ mobilization studies","volume":"68","author":"Sharif","year":"2003","journal-title":"Prostaglandins, Leukotrienes Essent. Fatty Acids"},{"key":"2026081416171410100_cit142","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0952-3278(98)90055-2","article-title":"Use of\na semi-automated, robotic radioimmunoassay to measure cAMP generated\nby activation of DP-, EP2- and IP-prostaglandin receptors\nin human ocular and other cell-types","volume":"59","author":"Crider","year":"1998","journal-title":"Prostaglandins,\nLeukotri Essential Fatty Acids"},{"key":"2026081416171410100_cit143","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/jop.1998.14.293","article-title":"Prostaglandin-stimulated\nadenylyl cyclase activity via a pharmacologically-defined EP2 receptor in human NPE cells","volume":"14","author":"Crider","year":"1998","journal-title":"J. Ocul. Pharmacol.\nTher."},{"key":"2026081416171410100_cit144","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/sj.bjp.0702490","article-title":"Prostaglandin DP\nreceptors positively coupled to adenylyl cyclase in embryonic bovine\ntracheal (EbTr) cells: pharmacological characterization using agonists\nand antagonists","volume":"127","author":"Crider","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit145","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1054\/plef.1999.0120","article-title":"Endogenous\nEP4 prostaglandin\nreceptors coupled positively to adenylyl cyclase in Chinese hamster\novary cells: pharmacological characterization","volume":"62","author":"Crider","year":"2000","journal-title":"Prostaglandins, Leukotrienes Essent. Fatty Acids"},{"key":"2026081416171410100_cit146","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1054\/plef.2001.0322","article-title":"Pharmacology\nof\nfunctional endogenous IP prostanoid receptors in NCB-20 cells: comparison\nwith binding data from human platelets","volume":"65","author":"Crider","year":"2001","journal-title":"Prostaglandins,\nLeukotrienes Essent. Fatty Acids"},{"key":"2026081416171410100_cit147","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1089\/108076802760116142","article-title":"Adenylyl cyclase\nactivity mediated\nby \u03b22-adrenoceptors in immortalized human trabecular meshwork\nand non-pigmented ciliary epithelial cells","volume":"18","author":"Crider","year":"2002","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit148","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1167\/iovs.02-1292","article-title":"Pharmacological\ncharacterization of a serotonin receptor (5HT7) stimulating\ncAMP production in human corneal epithelial cells","volume":"44","author":"Crider","year":"2003","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit149","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/108076801750125658","article-title":"Functional pharmacological\nevidence\nfor EP2 and EP4 prostanoid receptors in immortalized\nhuman trabecular meshwork and non-pigmented ciliary epithelial cells","volume":"17","author":"Crider","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0952-3278(98)90055-2","article-title":"Use of\na semi-automated, robotic radioimmunoassay to measure cAMP generated\nby activation of DP-, EP2- and IP-prostaglandin receptors\nin human ocular and other cell-types","volume":"59","author":"Crider","year":"1998","journal-title":"Prostaglandins,\nLeukotri Essential Fatty Acids"},{"key":"2026081416171410100_cit151","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0952-3278(98)90055-2","article-title":"Use of\na semi-automated, robotic radioimmunoassay to measure cAMP generated\nby activation of DP-, EP2- and IP-prostaglandin receptors\nin human ocular and other cell-types","volume":"59","author":"Crider","year":"1998","journal-title":"Prostaglandins,\nLeukotrienes Essent. Fatty Acids"},{"key":"2026081416171410100_cit152","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0022-3565(24)35032-3","article-title":"AL-8810:\na novel PGF2\u03b1 analog with selective antagonist effects\nat the FP prostaglandin receptor","volume":"290","author":"Griffin","year":"1999","journal-title":"J. Pharmacol\nExp Ther."},{"key":"2026081416171410100_cit153","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/jop.1999.15.323","article-title":"Quantitative\nautoradiographic visualization\nand pharmacology of FP-prostaglandin receptors in human eyes using\nthe novel phosphor-imaging technology","volume":"15","author":"Davis","year":"1999","journal-title":"J. Ocul.\nPharmacol. Ther."},{"key":"2026081416171410100_cit154","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/sj.bjp.0703525","article-title":"Pharmacological characterization\nof [3H]-prostaglandin E2 binding to the cloned\nhuman EP4 prostanoid receptor","volume":"130","author":"Davis","year":"2000","journal-title":"Br.\nJ. Pharmacol."},{"key":"2026081416171410100_cit155","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/108076801753266802","article-title":"Preclinical efficacy of travoprost, a potent\nand selective FP prostaglandin receptor agonist","volume":"17","author":"Hellberg","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit156","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0039-6257(02)00293-X","article-title":"Identification\nand characterization of the ocular hypotensive efficacy of Travoprost,\na potent and selective FP prostaglandin receptor agonist, and AL-6598,\na DP prostaglandin receptor agonist","volume":"47","author":"Hellberg","year":"2002","journal-title":"Surv. Ophthalmol."},{"key":"2026081416171410100_cit157","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/108076801753162726","article-title":"Levobetaxolol\n(Betaxon) and other \u03b2\u2013adrenergic antagonists: preclinical\npharmacology, IOP-lowering activity and sites of action in human eyes","volume":"17","author":"Sharif","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit158","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/108076803322660422","article-title":"Ocular\nhypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding\naffinities and selectivities, and agonist potencies at FP and other\nPG receptors in cultured cells","volume":"19","author":"Sharif","year":"2003","journal-title":"J. Ocul. Pharmacol.\nTher."},{"key":"2026081416171410100_cit159","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1749-6632.1989.tb46638.x","article-title":"Quantitative\nautoradiography of TRH receptors in discrete\nbrain regions of different mammalian species","volume":"553","author":"Sharif","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2026081416171410100_cit160","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/0196-9781(89)90135-6","article-title":"Discrete mapping of\nbrain mu and\ndelta opioid receptors using selective peptides: quantitative autoradiography,\nspecies differences and comparison with kappa receptors","volume":"10","author":"Sharif","year":"1989","journal-title":"Peptides"},{"key":"2026081416171410100_cit161","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/jop.2004.20.489","article-title":"Molecular\npharmacology of the ocular hypotensive DP\/EP2 class prostaglandin\nAL-6598 and localization of DP and EP2 receptor sites in\nhuman eyes","volume":"20","author":"Sharif","year":"2004","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit162","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1089\/108076803322473006","article-title":"Human\nciliary muscle responses to FP-class prostaglandin analogs: phosphoinositide\nhydrolysis, intracellular Ca2+-mobilization and MAP kinase\nactivation","volume":"19","author":"Sharif","year":"2003","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit163","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1167\/iovs.02-0323","article-title":"Human trabecular\nmeshwork cell responses induced by bimatoprost, travoprost, unoprostone,\nand other FP prostaglandin receptor agonist analogues","volume":"44","author":"Sharif","year":"2003","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit164","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/10807680260218489","article-title":"Agonist\nactivity\nof bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester\nand other prostaglandin analogs at the cloned human ciliary body FP\nprostaglandin receptor","volume":"18","author":"Sharif","year":"2002","journal-title":"J. Ocul. Pharmacol.\nTher."},{"key":"2026081416171410100_cit165","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1124\/jpet.102.042556","article-title":"Real-time intracellular\nCa2+-mobilization by travoprost acid, bimatoprost, unoprostone\nand other analogs via endogenous mouse, rat and cloned human FP prostaglandin\nreceptors","volume":"304","author":"Kelly","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026081416171410100_cit166","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/jop.2007.0076","article-title":"Cat iris\nsphincter smooth muscle contraction: comparison of FP-class prostaglandin\nanalog agonist activities","volume":"24","author":"Sharif","year":"2008","journal-title":"J. Ocul. Pharmacol.\nTher."},{"key":"2026081416171410100_cit167","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.plefa.2008.01.005","article-title":"Synthetic\nFP-class prostaglandin-induced contraction\nof rat uterus smooth muscle in vitro","volume":"78","author":"Sharif","year":"2008","journal-title":"Prostaglandins, Leukotrienes Essent. Fatty Acids"},{"issue":"30","key":"2026081416171410100_cit168","doi-asserted-by":"publisher","first-page":"e16597","DOI":"10.1097\/MD.0000000000016597","article-title":"Efficacy and\nsafety of prostaglandin analogues in primary open-angle glaucoma or\nocular hypertension patients: A meta-analysis","volume":"98","author":"Tang","year":"2019","journal-title":"Medicine (Philadelphia, PA, U. S.)"},{"key":"2026081416171410100_cit168a","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/108076803321637627","article-title":"The hydrolysis\nof the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor\nPGF2\u03b1 by human and rabbit ocular tissues","volume":"19","author":"Hellberg","year":"2003","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit169","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1016\/j.bmcl.2004.06.037","article-title":"AL-12182,\na novel 11-oxa prostaglandin analog with topical ocular hypotensive\nactivity in the monkey","volume":"14","author":"Selliah","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026081416171410100_cit170","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1089\/jop.2006.22.291","article-title":"Preclinical\npharmacology of AL-12182, a new ocular hypotensive 11-oxa-prostaglandin\nanalog","volume":"22","author":"Sharif","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit171","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.bmc.2008.11.070","article-title":"Discovery\nof 13-oxa prostaglandin analogs as novel antiglaucoma agents: synthesis\nand biological activity","volume":"17","author":"Feng","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"2026081416171410100_cit172","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1016\/j.bmc.2004.04.034","article-title":"15-Fluoro prostaglandin FP agonists: a new class of topical ocular\nhypotensives","volume":"12","author":"Klimko","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"2026081416171410100_cit173","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.6.1.45","article-title":"The side effects of the prostaglandin\nanalogues","volume":"6","author":"Hollo\u0301","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"2026081416171410100_cit174","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/108076804773710759","article-title":"Binding affinities\nof ocular hypotensive\n\u03b2-blockers levobetaxolol, levobunolol and timolol at endogenous\nguinea pig \u03b2 \u2013 adrenoceptors","volume":"20","author":"Sharif","year":"2004","journal-title":"J.\nOcul. Pharmacol. Ther."},{"key":"2026081416171410100_cit175","first-page":"93","article-title":"Levobetaxolol\nhydrochloride: a review of its pharmacology and use in the treatment\nof chronic open-angle glaucoma and ocular hypertension","volume":"1","author":"Quaranta","year":"2007","journal-title":"Clin Ophthalmol."},{"key":"2026081416171410100_cit176","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.bmcl.2009.12.012","article-title":"2,3-Diaminopyrines\nas rho kinase inhibitors","volume":"20","author":"Henderson","year":"2010","journal-title":"Bioorg. Med. Chem.\nLett."},{"key":"2026081416171410100_cit177","unstructured":"Hellberg, M. R., Sharif, N. A., and May, J. A.; \n               et al.  (2010) (Indazol-5-yl)-pyrazines and (1,3-hihydro-indol-2-one)-pyrazines\nfor treating glaucoma and controlling intraocular pressure. US PatentUS7655662."},{"key":"2026081416171410100_cit178","unstructured":"Chen, H.-H., Sharif, N. A., and Hellberg, M. R. (2011) Hydroxyamino- and amino-substituted pyridine analogs for treating\nrho kinase-mediated diseases and conditions. US PatentUS7867999."},{"key":"2026081416171410100_cit179","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.bmcl.2014.03.017","article-title":"In vivo\noptimization of 2,3-diaminopyrazine Rho kinase inhibitors","volume":"24","author":"Chen","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026081416171410100_cit180","first-page":"1877","article-title":"Rho-Rho\nkinase pathway in the actomyosin contraction and cell-matrix adhesion\nin immortalized human trabecular meshwork cells","volume":"17","author":"Ramachandran","year":"2011","journal-title":"Mol. Vision"},{"issue":"2238","key":"2026081416171410100_cit181","first-page":"2245","article-title":"The characteristics\nof [3H]-5-hydroxytrytamine binding to iris ciliary body\nof the rabbit","volume":"36","author":"Chidlow","year":"1995","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2026081416171410100_cit182","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1006\/exer.2001.1012","article-title":"[3H]-Serotonin release from bovine iris-ciliary body:\npharmacology\nof pre-junctional serotonin (5HT7) auto-receptors","volume":"73","author":"Harris","year":"2001","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit183","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/10807680260218506","article-title":"Pharmacology\nof serotonin receptors modulating electrically-induced [3H]-norepinephrine release from isolated mammalian iris-ciliary bodies","volume":"18","author":"Harris","year":"2002","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit184","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1124\/jpet.103.049528","article-title":"Evaluation\nof the ocular hypotensive response of serotonin 5HT1A and\n5HT2 receptor ligands in conscious ocular hypertensive\ncynomolgus monkeys","volume":"306","author":"May","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026081416171410100_cit185","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2174\/138945010791591278","article-title":"Serotonin-2 receptor agonists as\nnovel ocular hypotensive\nagents and their cellular mechanisms of action: novel drug targets\nfor glaucoma treatment","volume":"11","author":"Sharif","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"2026081416171410100_cit186","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1586\/eop.10.69","article-title":"Potential for serotonergic\nagents\nto treat elevated intraocular pressure and glaucoma: focus on 5HT2 receptor agonists","volume":"6","author":"Sharif","year":"2011","journal-title":"Expert Rev. Ophthalmol."},{"key":"2026081416171410100_cit187","unstructured":"May, J. A., Dean, T. R., Sharif, N. A., and Hellberg, M. R. (2003) Serotonergic 5HT2 agonists\nfor treating glaucoma. US PatentUS6664286."},{"key":"2026081416171410100_cit188","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1021\/jm030205t","article-title":"A novel\nand selective 5HT2 receptor agonist with ocular hypotensive\nactivity: (S)-(+)-1\ue5f8(2-aminopropyl)-8,9-dihydropyrano-[3,2-e]\u00adindole","volume":"46","author":"May","year":"2003","journal-title":"J. Med. Chem."},{"key":"2026081416171410100_cit189","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1021\/jm050663x","article-title":"1-((S)-2-Aminopropyl)-1H-indazol-6-ol:\na potent peripherally acting 5HT2 receptor agonist with\nocular hypotensive activity","volume":"49","author":"May","year":"2006","journal-title":"J. Med. Chem."},{"key":"2026081416171410100_cit190","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.pbb.2008.07.015","article-title":"Pharmacological\nproperties and discriminative stimulus effects of a novel and selective\n5HT2 receptor agonist, AL-38022A [(S)-2- (8,9- dihydro-7H-\npyrano\u00ad[2,3g]\u00adindazol-1-yl)-1-methylethylamine]","volume":"91","author":"May","year":"2009","journal-title":"Pharmacol., Biochem. Behav."},{"key":"2026081416171410100_cit191","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1021\/jm0100739","article-title":"1-[2-methoxy-5-(3-phenylpropyl)]-2-aminopropane\nunexpectedly shows 5HT2A serotonin receptor affinity and\nantagonist character","volume":"44","author":"Rangisetty","year":"2001","journal-title":"J. Med. Chem."},{"key":"2026081416171410100_cit192","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1021\/jm040082s","article-title":"\u03b2-Oxygenated analogues of the 5HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane","volume":"47","author":"Glennon","year":"2004","journal-title":"J. Med. Chem."},{"key":"2026081416171410100_cit193","first-page":"1040","article-title":"Serotonin receptor subtype mRNA expression\nin human ocular tissues determined by RT-PCR","volume":"12","author":"Sharif","year":"2006","journal-title":"Mol. Vis."},{"key":"2026081416171410100_cit194","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1124\/jpet.105.100172","article-title":"Pharmacological\nevidence for a functional\nserotonin-2B receptor subtype in a human uterine smooth muscle cell\nline","volume":"317","author":"Kelly","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026081416171410100_cit195","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1016\/j.bmcl.2007.03.073","article-title":"Novel\nbenzodifuran analogs as potent 5HT2A receptor agonists\nwith ocular hypotensive activity","volume":"17","author":"Feng","year":"2007","journal-title":"Bioorg. Med.\nChem. Lett."},{"key":"2026081416171410100_cit196","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/jop.2017.0123","article-title":"Serotonin-2B\/2C\nreceptors-mediate bovine ciliary muscle contraction: role in IOP regulation","volume":"34","author":"Ohia","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit197","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/jop.2017.0124","article-title":"Pharmacology\nof serotonin receptors causing contraction of bovine isolated posterior\nciliary arteries: role in ocular blood-flow modulation","volume":"34","author":"Njie-Mbye","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit198","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/jop.2006.22.389","article-title":"Serotonin-2\n(5HT2) receptor-mediated signal transduction in human ciliary\nmuscle cells: role in ocular hypotension","volume":"22","author":"Sharif","year":"2006","journal-title":"J.\nOcul. Pharmacol. Ther."},{"key":"2026081416171410100_cit199","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1167\/iovs.06-0062","article-title":"Human trabecular\nmeshwork cells express functional serotonin-2 (5HT2) receptors:\nrole in IOP reduction","volume":"47","author":"Sharif","year":"2006","journal-title":"Invest. Ophthalmol. Visual\nSci."},{"key":"2026081416171410100_cit200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jop.2006.0093","article-title":"AL-34662: a potent,\nselective, and efficacious ocular hypotensive serotonin-2 receptor\nagonist","volume":"23","author":"Sharif","year":"2007","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit201","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.exer.2008.10.003","article-title":"Cabergoline:\npharmacology, ocular hypotensive studies in multiple species, and\naqueous humor dynamic modulation in cynomolgus monkey eyes","volume":"88","author":"Sharif","year":"2009","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit202","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1211\/0022357044346","article-title":"Cloned\nhuman 5HT1A receptor pharmacology determined using agonist\nbinding and measurement of cAMP accumulation","volume":"56","author":"Sharif","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"2026081416171410100_cit203","unstructured":"May, J. A., Dean, T. R., Sharif, N. A., and Chen, H.-H. (2006) Serotonergic 5HT7 receptor compounds for treating ocular\nand CNS disorders. US PatentUS7060704."},{"key":"2026081416171410100_cit204","unstructured":"May, J. A., Dean, T. R., Sharif, N. A., and Chen, H.-H. (2007) Serotonergic 5HT7 receptor compounds for treating ocular\nand CNS disorders. US PatentUS7285553."},{"issue":"1","key":"2026081416171410100_cit205","doi-asserted-by":"publisher","first-page":"555601","DOI":"10.19080\/JOJO.2017.03.555601","article-title":"Prospects of treating ocular hypertension and glaucoma\nwith peptidic and non-peptide kinin mimetic drugs","volume":"3","author":"Sharif","year":"2017","journal-title":"JOJ. Ophthalmol"},{"key":"2026081416171410100_cit206","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1006\/exer.1996.0157","article-title":"Pharmacological characterization\nof bradykinin receptors coupled to phosphoinositide turnover in SV40\nimmortalized human trabecular meshwork cells","volume":"63","author":"Sharif","year":"1996","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit207","unstructured":"Sharif, N. A.\n           (2002). Non-peptide bradykinin antagonists for use in controlling intraocular\npressure and treating glaucoma. US PatentUS6500831."},{"key":"2026081416171410100_cit208","doi-asserted-by":"publisher","first-page":"FR190997","DOI":"10.1038\/sj.bjp.0701813","article-title":"Pharmacological characterization of a nonpeptide bradykinin\nB2 receptor antagonist, FR165649, and agonist","volume":"124","author":"Asano","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit209","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0304-3940(88)90496-X","article-title":"Bradykinin\ninduced accumulation of [3H]\u00adinositol 1 phosphate in human embryonic\npituitary tumor cells by activation of a B2 receptor","volume":"86","author":"Sharif","year":"1988","journal-title":"Neurosci. Lett."},{"key":"2026081416171410100_cit210","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1471-4159.1991.tb02018.x","article-title":"Flow cytometric\nanalysis of internal calcium mobilization via a B2 bradykinin\nreceptor in a subclone of PC12 cells","volume":"56","author":"Ransom","year":"1991","journal-title":"J. Neurochem."},{"key":"2026081416171410100_cit211","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/BF00975053","article-title":"The neuropeptide\nbradykinin stimulates\nphosphoinositide turnover in HSDM1C1 cells: B2 antagonist\nsensitive responses and receptor binding studies","volume":"12","author":"Sharif","year":"1993","journal-title":"Neurochem. Res."},{"key":"2026081416171410100_cit212","unstructured":"Sharif, N. A.\n           (2010) Use of bradykinin and related\nB2R agonists to treat ocular\nhypertension and glaucoma. US PatentUS7807629."},{"key":"2026081416171410100_cit213","unstructured":"Sharif, N. A.\n           (2012) Use of non-peptidic bradykinin receptor agonists\nto treat ocular\nhypertension and glaucoma. US PatentUS8173668."},{"key":"2026081416171410100_cit214","unstructured":"Combrink, K., Mohapatra, S., and Hellberg, M. R.; \n               et al.  (2012) Bradykinin receptor agonists and uses\nthereof to\ntreat ocular hypertension and glaucoma. US\nPatentUS8252793."},{"key":"2026081416171410100_cit215","first-page":"1356","article-title":"Protein\nexpression, biochemical pharmacology of signal transduction, and relation\nto IOP modulation by bradykinin B2-receptors in ciliary\nmuscle","volume":"19","author":"Sharif","year":"2013","journal-title":"Mol. Vision"},{"key":"2026081416171410100_cit216","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/02713683.2013.816324","article-title":"Human\nnon-pigmented ciliary epithelium bradykinin B2-receptors:\nreceptor localization, pharmacological characterization of intracellular\nCa2+ mobilization, and prostaglandin secretion","volume":"39","author":"Sharif","year":"2014","journal-title":"Curr. Eye Res."},{"key":"2026081416171410100_cit217","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/jop.2013.0105","article-title":"Trabecular\nmeshwork bradykinin receptors: mRNA levels, immunohistochemical visualization,\nsignaling processes pharmacology and linkage to IOP changes","volume":"30","author":"Sharif","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit218","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ddr.21174","article-title":"FR-190997,\na non-peptide bradykinin B2-receptor partial agonist, is\na potent and efficacious intraocular pressure lowering agent in ocular\nhypertensive cynomolgus monkeys","volume":"75","author":"Sharif","year":"2014","journal-title":"Drug Dev. Res."},{"key":"2026081416171410100_cit219","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.exer.2014.10.008","article-title":"Preclinical\npharmacology, ocular tolerability and ocular hypotensive efficacy\nof a novel non-peptide bradykinin mimetic small molecule","volume":"128","author":"Sharif","year":"2014","journal-title":"Exp. Eye Res."},{"key":"2026081416171410100_cit220","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5318\/wjo.v6.i3.20","article-title":"Human ciliary\nmuscle cell responses to kinins: activation of ERK1\/2 and pro-matrix\nmetalloproteinases secretion","volume":"6","author":"Sharif","year":"2016","journal-title":"World J. Ophthalmol."},{"key":"2026081416171410100_cit221","first-page":"2883","article-title":"BK2A78:\na novel non-peptide bradykinin B2 agonist lowers intraocular\npressure (IOP) in ocular hypertensive Cynomolgus monkeys","author":"Prasanna","year":"2014","journal-title":"ARVO Abst. #"},{"key":"2026081416171410100_cit222","doi-asserted-by":"publisher","first-page":"3","DOI":"10.23937\/2378-346X\/1410031","article-title":"Ocular hypotensive\nactivity of a non-peptide bradykinin B2-receptor antagonist (WIN-64338)\nin Dutch-Belt rabbits: a case of poly-pharmacology in action","volume":"2","author":"Sharif","year":"2015","journal-title":"Int. J. Ophthalmol Clin Res."},{"key":"2026081416171410100_cit223","unstructured":"Ellis, D., Scheibler, L., and Sharif, N. A. (2017) Prostaglandin conjugates and derivatives for treating\nglaucoma and\nocular hypertension. US PatentUS9604949 B2."},{"key":"2026081416171410100_cit224","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1167\/iovs.17-22745","article-title":"Pharmacologic\ncharacterization of omidenepag isopropyl, a novel selective EP2 receptor\nagonist, as an ocular hypotensive agent","volume":"59","author":"Kirihara","year":"2018","journal-title":"Invest.\nOphthalmol. Visual Sci."},{"key":"2026081416171410100_cit225","unstructured":"Kirihara, T., Shimizaki, A., and Sharif, N. A. (2015) Prophylactic and\/or therapeutic agent containing\npyridylamino acetic acid compound. Japanese Patent; submitted; PCT\nfiled 7th July 2016."},{"key":"2026081416171410100_cit226","unstructured":"Kirihara, T., Shimizaki, A., and Sharif, N. A. (2018) Prophylactic and\/or therapeutic agent containing pyridylamino acetic\nacid compound. US Patent ApplicationUS2018\/ 0200239 A1."},{"key":"2026081416171410100_cit227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.08817","article-title":"A novel non-prostaglandin\nEP2-receptor agonist for glaucoma treatment: Omidenepag Isopropyl\n(DE-117)","volume":"34","author":"Sharif","year":"2020","journal-title":"FASEB J."},{"key":"2026081416171410100_cit228","unstructured":"Sharif, N. A., and Griffin, B. W. (2002) 11\u03b2-fluoro-15\u03b2-hydroxy-PGF2\u03b1 analogs\nas FP receptor antagonists. US PatentUS6441033."},{"key":"2026081416171410100_cit229","unstructured":"Sharif, N. A., and Griffin, B. W. (2003) 11-Deoxy-16-fluoro-PGF2\u03b1 and 11\u03b2-fluoro-15-\u03b2-hydroxy-PGF2\u03b1 analogs as FP receptor antagonists. US PatentUS6649655."},{"key":"2026081416171410100_cit230","unstructured":"Sharif, N. A., and Griffin, B. W. (2002) Treatment of FP receptor activation-related disorders, e.g. ocular\nhyperemia, involves use of 11-deoxy-16-fluoro-PGF2\u03b1 analogs. US PatentUS6492417."},{"key":"2026081416171410100_cit231","unstructured":"Sharif, N. A., and Griffin, B. W. (2003) 11\u03b2-fluoro-15 \u03b2-hydroxy-PGF2\u03b1 analogs\nas FP receptor antagonists. US PatentUS6649655."},{"key":"2026081416171410100_cit232","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1211\/0022357001777586","article-title":"AL-3138 antagonizes\nFP prostanoid receptor-mediated inositol phosphates generation: comparison\nwith some purported FP antagonists","volume":"52","author":"Sharif","year":"2000","journal-title":"J. Pharm.\nPharmacol."},{"key":"2026081416171410100_cit233","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/bph.14335","article-title":"Prostaglandin FP receptor antagonists:\ndiscovery, pharmacological characterization and therapeutic utility","volume":"176","author":"Sharif","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"2026081416171410100_cit234","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1167\/iovs.04-0993","article-title":"Acute effects of\nPGF2\u03b1 on MMP-2 secretion from human ciliary muscle\ncells: a PKC- and ERK-dependent process","volume":"46","author":"Husain","year":"2005","journal-title":"Invest.\nOphthalmol. Visual Sci."},{"key":"2026081416171410100_cit235","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1167\/iovs.05-0760","article-title":"Vasoactive\nresponses of U46619, PGF2alpha, latanoprost, and travoprost in isolated\nporcine ciliary arteries","volume":"47","author":"Vysniauskiene","year":"2006","journal-title":"Invest Ophthalmol\nVis Sci."},{"key":"2026081416171410100_cit236","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1096\/fj.04-3626fje","article-title":"Latanoprost\ninduces matrix metalloproteinase-1 expression in human nonpigmented\nciliary epithelial cells through a cyclooxygenase-2-dependent mechanism","volume":"19","author":"Hinz","year":"2005","journal-title":"FASEB J."},{"key":"2026081416171410100_cit237","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1167\/iovs.05-0527","article-title":"Endothelin antagonism: effects of FP receptor\nagonists prostaglandin F2alpha and fluprostenol on trabecular meshwork\ncontractility","volume":"47","author":"Thieme","year":"2006","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit238","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1167\/iovs.06-0896","article-title":"Evidence for the\ninvolvement of cannabinoid\nCB1 receptors in the bimatoprost-induced contractions on the human\nisolated ciliary muscle","volume":"48","author":"Romano","year":"2007","journal-title":"Invest. Ophthalmol.\nVisual Sci."},{"key":"2026081416171410100_cit239","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0014-2999(01)01486-8","article-title":"Bimatoprost and\nits free acid are prostaglandin FP receptor agonists","volume":"432","author":"Sharif","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"2026081416171410100_cit240","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1167\/iovs.15-17693","article-title":"Activation\nof prostaglandin FP and EP2 receptors differently modulates\nmyofibroblast transition in a model of adult primary human trabecular\nmeshwork cells","volume":"57","author":"Kalouche","year":"2016","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit241","doi-asserted-by":"publisher","first-page":"e0232591","DOI":"10.1371\/journal.pone.0232591","article-title":"Stanniocalcin-1\n(STC-1), a downstream effector molecule in latanoprost signaling,\nacts independent of the FP receptor for intraocular pressure reduction","volume":"15","author":"Roddy","year":"2020","journal-title":"PLoS One"},{"key":"2026081416171410100_cit242","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/infdis\/jiu299","article-title":"Role of prostaglandin\nF2\u03b1 production in lipid\nbodies from Leishmania infantum chagasi: insights on virulence","volume":"210","author":"Araujo-Santos","year":"2014","journal-title":"J. Infect. Dis."},{"key":"2026081416171410100_cit243","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1742-2094-10-132","article-title":"Prostaglandin\nF2\u03b1 FP receptor antagonist improves outcomes after\nexperimental traumatic brain injury","volume":"10","author":"Glushakov","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"2026081416171410100_cit244","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.plefa.2014.08.004","article-title":"Prostaglandin F2\u03b1 FP receptor inhibitor reduces\ndemyelination and motor dysfunction in a cuprizone-induced multiple\nsclerosis mouse model","volume":"91","author":"Iwasa","year":"2014","journal-title":"Prostaglandins, Leukotrienes\nEssent. Fatty Acids"},{"key":"2026081416171410100_cit245","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nbd.2012.06.003","article-title":"Prostaglandin FP receptor inhibitor reduces ischemic brain damage\nand neurotoxicity","volume":"8","author":"Kim","year":"2012","journal-title":"Neurobiol Dis."},{"key":"2026081416171410100_cit246","doi-asserted-by":"publisher","first-page":"104780","DOI":"10.1016\/j.nbd.2020.104780","article-title":"The antagonism of prostaglandin FP receptors\ninhibits the evolution\nof spreading depolarization in an experimental model of global forebrain\nischemia","volume":"137","author":"Varga","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"2026081416171410100_cit247","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001481R","article-title":"Prostaglandin\nF2\u03b1 receptor antagonist attenuates LPS-induced systemic inflammatory\nresponse in mice","author":"Maehara","year":"2020","journal-title":"FASEB J."},{"issue":"Suppl. 4","key":"2026081416171410100_cit248","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/S0039-6257(01)00224-7","article-title":"The pharmacology\nof bimatoprost (Lumigan)","volume":"45","author":"Woodward","year":"2001","journal-title":"Surv. Ophthalmol."},{"issue":"suppl 1","key":"2026081416171410100_cit249","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S0039-6257(02)00323-5","article-title":"The hydrolysis\nof bimatoprost in corneal tissue generates a potent prostanoid FP\nreceptor agonist","volume":"47","author":"Maxey","year":"2002","journal-title":"Surv. Ophthalmol."},{"key":"2026081416171410100_cit250","article-title":"Bimatoprost hydrolysis\nto 17-phenyl-PGF2\u03b1 by human and rabbit ocular tissues\nand agonist activity of bimatoprost and 17-phenyl-PGF2\u03b1","author":"Sharif","year":"2002","journal-title":"Assoc. Res. Vis. Ophthalmol. (ARVO)"},{"key":"2026081416171410100_cit251","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.ophtha.2004.06.028","article-title":"Detection\nof the free acid of bimatoprost in aqueous humor samples from human\neyes treated with bimatoprost before cataract surgery","volume":"111","author":"Camras","year":"2004","journal-title":"Ophthalmology"},{"key":"2026081416171410100_cit252","first-page":"862","article-title":"Bimatoprost,\nthe prodrug of a prostaglandin analogue","volume":"92","author":"Camras","year":"2008","journal-title":"Br\nJ. Ophthalmol."},{"key":"2026081416171410100_cit253","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/108076803762718105","article-title":"Hydrolysis\nof bimatoprost (Lumigan) to its free acid by ocular tissue in vitro","volume":"19","author":"Davies","year":"2003","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit254","article-title":"In vitro hydrolysis\nof bimatoprost in bovine cornea","author":"Kriatchko","year":"2003","journal-title":"Assoc. Res.\nVis. Ophthalmol. (ARVO)"},{"key":"2026081416171410100_cit255","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/jop.2009.0098","article-title":"Aqueous\nhumor concentrations of bimatoprost free acid, bimatoprost and travoprost\nfree acid in cataract surgical patients administered multiple topical\nocular doses of LUMIGAN or TRAVATAN","volume":"26","author":"Faulkner","year":"2010","journal-title":"J. Ocul.\nPharmacol. Ther."},{"key":"2026081416171410100_cit256","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1586\/eop.09.40","article-title":"Update and commentary on the prodrug\nbimatoprost and a putative prostamide receptor","volume":"4","author":"Sharif","year":"2009","journal-title":"Expert Rev. Ophthalmol."},{"key":"2026081416171410100_cit257","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0002-9394(03)00658-5","article-title":"The prostaglandin\nwars","volume":"136","author":"Kaufman","year":"2003","journal-title":"Am. J.\nOphthalmol."},{"key":"2026081416171410100_cit258","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0014-4835(89)90011-0","article-title":"Increased\nuveoscleral outflow as a possible mechanism of ocular hypotension\ncaused by prostaglandin F2 alpha-1-isopropyl ester in the cynomolgus\nmonkey","volume":"48","author":"Nilsson","year":"1989","journal-title":"Exp. Eye Res."},{"issue":"Suppl 4","key":"2026081416171410100_cit259","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.1016\/S0039-6257(01)00219-3","article-title":"Bimatoprost Study Groups\n1 and 2.\nSix-month comparison of bimatoprost once-daily and twice-daily with\ntimolol twice-daily in patients with elevated intraocular pressure","volume":"45","author":"Sherwood","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"2026081416171410100_cit260","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S0002-9394(01)00831-5","article-title":"Potential\nmechanism for the additivity of pilocarpine and latanoprost","volume":"131","author":"Toris","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"2026081416171410100_cit261","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1001\/archopht.122.12.1782","article-title":"Increase in outflow\nfacility with unoprostone treatment in ocular hypertensive patients","volume":"122","author":"Toris","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"2026081416171410100_cit262","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/IJG.0b013e31802fc6d3","article-title":"Effects\nof travoprost on aqueous humor dynamics in patients with elevated\nintraocular pressure","volume":"16","author":"Toris","year":"2007","journal-title":"J. Glaucoma"},{"key":"2026081416171410100_cit263","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.ajo.2006.01.049","article-title":"Sustained\neffect of travoprost on diurnal and nocturnal intraocular pressure","volume":"141","author":"Sit","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"2026081416171410100_cit264","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10384-008-0617-8","article-title":"Effect\nof travoprost on intraocular pressure during 12 months of treatment\nfor normal-tension glaucoma","volume":"53","author":"Suh","year":"2009","journal-title":"Jpn. J. Ophthalmol."},{"key":"2026081416171410100_cit265","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.ophtha.2014.12.038","article-title":"Association\nbetween SNPs of metalloproteinases and prostaglandin F2\u03b1 receptor\ngenes and latanoprost response in open-angle glaucoma","volume":"122","author":"Ussa","year":"2015","journal-title":"Ophthalmology"},{"key":"2026081416171410100_cit266","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1089\/jop.2019.0146","article-title":"Matrix\nmetalloproteinases and glaucoma treatment","volume":"36","author":"Weinreb","year":"2020","journal-title":"J.\nOcul. Pharmacol. Ther."},{"key":"2026081416171410100_cit267","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ajo.2007.09.001","article-title":"Prostaglandins\nincrease trabecular meshwork outflow facility in cultured human anterior\nsegments","volume":"145","author":"Bahler","year":"2008","journal-title":"Am. J. Ophthalmol."},{"issue":"Suppl1","key":"2026081416171410100_cit268","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","article-title":"Update\non the mechanism\nof action of topical prostaglandins for intraocular pressure reduction","volume":"53","author":"Toris","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"2026081416171410100_cit269","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.ophtha.2004.02.006","article-title":"Mechanism\nof ocular hypotensive action of bimatoprost (Lumigan) in patients\nwith ocular hypertension or glaucoma","volume":"111","author":"Christiansen","year":"2004","journal-title":"Ophthalmology"},{"key":"2026081416171410100_cit270","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ophtha.2007.07.002","article-title":"Mechanism of action of bimatoprost, latanoprost, and travoprost in\nhealthy subjects. A crossover study","volume":"115","author":"Lim","year":"2008","journal-title":"Ophthalmology"},{"key":"2026081416171410100_cit271","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00417-003-0835-1","article-title":"The influence of Latanoprost 0.005% on aqueous humor flow and outflow\nfacility in glaucoma patients: a double-masked placebo-controlled\nclinical study","volume":"242","author":"Dinslage","year":"2004","journal-title":"Graefe's Arch. Clin. Exp.\nOphthalmol."},{"key":"2026081416171410100_cit272","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1167\/iovs.03-0990","article-title":"Effect\nof latanoprost on outflow facility in the mouse","volume":"45","author":"Crowston","year":"2004","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit273","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/jop.2005.21.121","article-title":"Ocular\nhypotensive\nDP-class prostaglandin receptor affinities determined by quantitative\nautoradiography on human eye sections","volume":"21","author":"Sharif","year":"2005","journal-title":"J. Ocul.\nPharmacol. Ther."},{"key":"2026081416171410100_cit274","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1167\/iovs.14-14515","article-title":"Nitric oxide (NO): an emerging target for the treatment of glaucoma","volume":"55","author":"Cavet","year":"2014","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081416171410100_cit275","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive\nintraocular pressure-lowering effects of the rho kinase inhibitor\nripasudil (K-115) combined with timolol or latanoprost: a report of\n2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"2026081416171410100_cit276","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery\nand Preclinical Development of Netarsudil, a Novel Ocular Hypotensive\nAgent for the Treatment of Glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J. Ocul.\nPharmacol. Ther."},{"key":"2026081416171410100_cit277","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40662-019-0162-1","article-title":"Ab externo\nimplantation of the MicroShunt, a poly (styrene-block-isobutylene-blockstyrene)\nsurgical device for the treatment of primary open-angle glaucoma:\na review","volume":"6","author":"Sadruddin","year":"2019","journal-title":"Eye Vision"},{"key":"2026081416171410100_cit278","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","article-title":"Fixed-combination\nintraocular pressure-lowering therapy for glaucoma and ocular hypertension:\nadvantages in clinical practice","volume":"15","author":"Hollo","year":"2014","journal-title":"Expert Opin.\nPharmacother."},{"key":"2026081416171410100_cit279","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1523\/JNEUROSCI.5956-09.2010","article-title":"Metabolic\nvulnerability disposes retinal ganglion cell axons to dysfunction\nin a model of glaucomatous degeneration","volume":"30","author":"Baltan","year":"2010","journal-title":"J.\nNeurosci."},{"key":"2026081416171410100_cit280","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/glia.22825","article-title":"An energy\ntheory of glaucoma","volume":"63","author":"Li","year":"2015","journal-title":"Glia"},{"key":"2026081416171410100_cit281","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin\nB3 modulates mitochondrial vulnerability and prevents glaucoma in\naged mice","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"2026081416171410100_cit282","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ceo.13818","article-title":"Improvement in inner\nretinal function in glaucoma with nicotinamide (vitamin B3) supplementation:\nA crossover randomized clinical trial","volume":"48","author":"Hui","year":"2020","journal-title":"Clin\nExperiment Ophthalmol. 2020 Jul"},{"key":"2026081416171410100_cit283","doi-asserted-by":"publisher","first-page":"eaan2788","DOI":"10.1126\/science.aan2788","article-title":"Spermidine in health and disease","volume":"359","author":"Madeo","year":"2018","journal-title":"Science"},{"key":"2026081416171410100_cit284","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.2174\/1570159X15666170808120633","article-title":"Neuroprotective role\nof agmatine in neurological diseases","volume":"16","author":"Xu","year":"2018","journal-title":"Curr.\nNeuropharmacol."},{"key":"2026081416171410100_cit285","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/jop.2017.0085","article-title":"Regulation of excitatory amino acid transmission in the retina: studies\non neuroprotection","volume":"34","author":"Opere","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2026081416171410100_cit286","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.ophtha.2010.08.049","article-title":"Reversal\nof retinal ganglion cell dysfunction after surgical reduction of intraocular\npressure","volume":"117","author":"Sehi","year":"2010","journal-title":"Ophthalmology"}],"container-title":["ACS Pharmacology &amp; Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsptsci.0c00137","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/3\/6\/1391\/6275656\/pt0c00137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/3\/6\/1391\/6275656\/pt0c00137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:17:29Z","timestamp":1786738649000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article\/3\/6\/1391\/611979\/Discovery-to-Launch-of-Anti-allergy-Emadine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":287,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,5]]},"published-print":{"date-parts":[[2020,12,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acsptsci.0c00137","relation":{},"ISSN":["2575-9108"],"issn-type":[{"value":"2575-9108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}